News
-
-
-
PRESS RELEASE
EQS-Adhoc: Merck KGaA: Merck confirms late-stage discussions with SpringWorks Therapeutics, Inc. on potential acquisition
Merck KGaA confirms late-stage discussions with SpringWorks Therapeutics, Inc. on potential acquisition, at around USD 47 per share. No final decision or binding agreement yet -
-
-
-
-
-
-